Article Text
PDF
Statistics from Altmetric.com
- hormone replacement therapy
- postmenopause
- breast neoplasms
- coronary disease
- cerebrovascular accident
- venous thrombosis
- dementia
- fractures
- colorectal neoplasms
Q In perimenopausal and postmenopausal women, does long term use of hormone therapy (HT) affect the risk of death, vascular disease, cancer, dementia, and other chronic diseases?
Clinical impact ratings GP/FP/Primary care ★★★★★★☆ Endocrine ★★★★★★☆ Geriatrics ★★★★★★☆ Gynaecology ★★★★★★★
METHODS
Data sources:
Medline, EMBASE/Excerpta Medica, Biological Abstracts, Cochrane Central Register of Controlled Trials, and Cochrane Menstrual Disorders and Subfertility Group Trials Register (to November 2004); UK National Research Register and registers from the UK National Health Service Centre for Reviews and Dissemination (to January 2004); reference lists of relevant articles; and pharmaceutical companies.
Study selection and assessment:
randomised, double blind, placebo controlled trials (RCTs) that evaluated the effect of long term HT use (⩾1 y) on death or serious chronic diseases in perimenopausal or postmenopausal women. HT consisted of oestrogen, alone or combined with progestogen, administered by oral, transdermal, subcutaneous, or intranasal routes.
Outcomes:
mortality, heart disease, …
Footnotes
-
For correspondence: Dr C M Farquhar, University of Auckland, New Zealand. C.farquhar{at}auckland.ac.nz
-
Source of funding: no external funding.